Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9960496 | 0.86 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL9960629 | 0.77 | RAB9A (0.42) | RAB9ANPC1KMT2AALDH1A1LMNA | |
| SCHEMBL9960717 | 0.77 | RAB9A (0.36) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL9960807 | 0.77 | LMNA (0.47) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL27926816 | 0.76 | POLB (0.39) | SMN1; SMN2KMT2AMEN1NPSR1KDM4E | |
| SCHEMBL28806370 | 0.76 | ELANE (0.41) | SMN1; SMN2KMT2AMEN1NPSR1KDM4E | |
| SCHEMBL9960746 | 0.75 | ALDH1A1 (0.45) | SMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL28161568 | 0.75 | POLB (0.38) | ALDH1A1LMNAPOLB | |
| SCHEMBL27926861 | 0.75 | POLB (0.38) | ALDH1A1LMNAPOLB | |
| SCHEMBL9960651 | 0.75 | HSD17B1 (0.41) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130324600-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-12-05 | — | — | US | claimed |
| EP-2655311-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | claimed |
| WO-2012085189-A1 | INGENOL-3-ACYLATES I | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | claimed |
| US-9388124-B2 | Ingenol-3-acylates I | LEO LABORATORIES LIMITED (IE) | 2016-07-12 | — | — | US | disclosed |
| US-20130324600-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-12-05 | — | — | US | disclosed |
| EP-2655311-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085189-A1 | INGENOL-3-ACYLATES I | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324600-A1 | INGENOL-3-ACYLATES I | CXCL8, MMP8, CASP8 | RAB9A 1139/4885SMN1; SMN2 4085/4885NPC1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.